Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Glaxosmithkline Intellectual Property Development Limited Gsk Medicines Research Centre has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit.
KEOGH, MATTHEW R is the busiest examiner, with 1 pending matter. The narrow assignment supports a matter-specific prosecution plan centered on the individual examination record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §112 only | 2 (18%) |
| Double-patenting only | 2 (18%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19090900 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | DAVIS, BRIAN J | — |
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | — |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18930210 | COMPOSITIONS AND METHODS FOR PRODUCING PRIMORDIAL GERM CELL-LIKE CELLS | KIM, TAEYOON | — |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | — |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | — |
| 18930210 | COMPOSITIONS AND METHODS FOR PRODUCING PRIMORDIAL GERM CELL-LIKE CELLS | KIM, TAEYOON | — |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | — |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | — |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | — |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1622 | 1 |
| 1658 | 1 |
| 1624 | 1 |
| 1643 | 1 |
| 1625 | 1 |
| 1675 | 1 |
| 1615 | 1 |
| 1644 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19090900 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | DAVIS, BRIAN J | 1614 | DP | Non-Final OA | — | Pending | Mar 26, 2025 |
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | 1622 | DP | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18930210 | COMPOSITIONS AND METHODS FOR PRODUCING PRIMORDIAL GERM CELL-LIKE CELLS | KIM, TAEYOON | — | §102§103§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 1625 | §101§112 | Non-Final OA | 53d | Pending | Dec 13, 2023 |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | 1675 | §102§103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18098792 | ANTIGEN BINDING PROTEINS | BELYAVSKYI, MICHAIL A | 1644 | §112DP | Final Rejection | — | Pending | Jan 19, 2023 |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | SCHMITT, MICHAEL J | 1629 | §112Other | Final Rejection | 29d | Pending | Aug 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlaxosmithkline Intellectual Property Development Limited has 11 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Brian J Davis has the most, with 1 of Glaxosmithkline Intellectual Property Development Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
